Image Credit source: File Photo
As before, from June 1, Indians will no longer need a vaccination certificate before travelling. Especially this approval has been given in view of travel. The approval of this vaccine was being awaited for a long time.
Good news has come to the fore for Bharat Biotech’s corona vaccine, Covaccine, prepared in India. Germany has approved the Covaccine. This approval was being awaited for a long time. Due to this, Indians traveling to Germany are going to get a big relief. Let us tell you that as before, from June 1, Indians will not be required to give a vaccination certificate before traveling. Especially this approval has been given in view of travel.
At the same time, earlier the World Health Organization (WHO) had banned the supply of Covaxin. Giving information about this, the World Health Organization said that it has stopped the supply of COVID-19 covaccine manufactured by Bharat Biotech through United Nations agencies. This restriction was imposed so that the defects found in the inspection and upgrade of the manufacturing facilities could be corrected.
There was a ban on the supply of covaccine
According to the WHO statement, the countries receiving the vaccine were asked to take appropriate action, but did not say what action would be taken. The WHO had said the vaccine was effective and there was no concern about its safety, but the suspension would result in a disruption in the supply of covaccine. The suspension was taken in response to the results of the WHO Post Emergency Use Listing (EUL) inspection from March 14 to 22.
At the same time, before this, the US Food and Drug Administration (FDA) has lifted the ban on Phase II of the three clinical trials of Bharat Biotech’s COVID-19 vaccine Covaccine. This information was given in a statement issued by Okugen Inc., partner of Bharat Biotech for this vaccine in the US and Canada. It was said in the statement that, we are very happy that we can proceed with our clinical trial for Covaccine. We believe the need to provide an additional, different type of vaccine remains a priority.
: Language Inputs
“This post is sourced from newspapers, magazines and third-party websites. For more information please check NewsNCR Disclaimer“
.